Romidepsin is effective and well-tolerated in patients ≥60 years old with relapsed or refractory peripheral T-cell lymphoma (PTCL): analysis from phase 2 trials.

Authors
Journal	Clinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 12 Issue 2 Suppl 5 Pg. 17-8 (Feb 2014) ISSN: 1543-0790 [Print] United States
PMID	24852793 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References	Antibiotics, Antineoplastic Depsipeptides romidepsin
Topics	Aged Antibiotics, Antineoplastic (therapeutic use) Depsipeptides (adverse effects, therapeutic use) Humans Lymphoma, T-Cell, Peripheral (drug therapy) Middle Aged Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!